PBM
Psyence Biomedical Ltd.
NASDAQ · Healthcare · Biotechnology · CA
$4.54
+2.48%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -40.2%
- EPS
- +1804.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -70.3%
- Net income
- —
- EPS
- -100.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026